Can You Smoke Weed With MS? Benefits and Risks

Many people with multiple sclerosis do use cannabis, and a meaningful body of clinical evidence supports some of its benefits, particularly for spasticity and pain. But “can you” is really two questions: is it likely to help, and what might it cost you? The answer to both depends on which symptoms you’re managing, how you use it, and whether you’re aware of the cognitive and psychiatric risks that tend to get left out of the conversation. Roughly one in five people with MS currently uses cannabis for symptom management, and the gap between what users report and what controlled studies show is worth understanding before you light up or try any other form.

Spasticity Is Where the Evidence Is Strongest

If there’s one symptom where cannabis has earned its reputation in MS, it’s spasticity, the muscle stiffness and involuntary tightness that can make movement painful and exhausting. In a randomized, placebo-controlled trial of smoked cannabis, participants experienced an average reduction of about 2.74 points more than placebo on a standard spasticity scale, a clinically meaningful difference.¹ A 2025 systematic review and meta-analysis pooling data across multiple studies confirmed that cannabis-based treatments showed notable improvements in spasticity scores overall, with longer-term use producing larger effects than short-term trials.²

There’s an important nuance here that often gets lost. When neurologists measure spasticity “objectively,” using clinical scales that assess how stiff a muscle actually is during a physical exam, cannabis doesn’t always move the needle. But when patients rate their own spasticity, how tight and uncomfortable they feel, the improvement is consistent. The American Academy of Neurology acknowledged this split directly in its guideline, noting that oral cannabis extract is effective for patient-reported spasticity symptoms while probably ineffective for objective spasticity measures in the short term.³ That doesn’t mean the benefit is imaginary. It likely means cannabis is changing the sensory experience of spasticity, reducing the pain and discomfort it produces, without fundamentally altering the underlying muscle tone. For someone living with daily stiffness, that distinction matters less than it sounds.

Pain Relief Is Real but Not Universal

Central pain in MS, the burning, stabbing, or squeezing sensations caused by nerve damage in the brain and spinal cord, is notoriously difficult to treat. Standard painkillers often don’t work well for it. Cannabis-based medicine has shown genuine benefit here. In a randomized controlled trial, a cannabis-based treatment reduced mean pain intensity significantly more than placebo, and sleep disturbance dropped alongside it.⁴ A broader review of the evidence found that oral cannabinoids are effective for treating MS pain and spasticity, while evidence for other MS symptoms was less consistent.⁵

In a retrospective review of a neurology outpatient clinic, about 72% of patients who started medical cannabis reported pain improvement, making it the most commonly relieved symptom.⁶ Pain relief and spasticity relief are likely intertwined for many users, since spasticity itself can be painful. This may be part of why patients often rate their improvement more favorably than clinical measures capture.

The AAN guideline distinguished between different types of pain: oral cannabis extract earned the strongest recommendation (Level A) for pain excluding central neuropathic pain, while THC and nabiximols were rated as probably effective (Level B).³ So the type of pain you have shapes how confident your neurologist might be about recommending cannabis.

Bladder Problems and Sleep

Overactive bladder is one of those MS symptoms that erodes quality of life relentlessly: urgency, frequency, getting up multiple times a night, and incontinence. There’s emerging evidence that cannabis helps here too. A pilot study of a THC/CBD oromucosal spray in MS patients with overactive bladder found that treatment significantly reduced overactive bladder symptoms.⁷ An earlier open-label pilot study reported that urgency, incontinence episodes, frequency, and nighttime urination all decreased significantly during cannabis-based treatment, with few troublesome side effects.⁸

The AAN’s systematic review gave nabiximols a “probably effective” rating for reducing daily bladder voids, though it rated THC and oral cannabis extract as probably ineffective for broader bladder complaints.⁹ The evidence is thinner here than for spasticity or pain, and these were small pilot studies, not large randomized trials. But the signal is encouraging enough that it’s worth discussing with a neurologist if bladder dysfunction is a major issue for you.

Sleep improvement gets reported frequently by patients who use cannabis for MS. In the outpatient retrospective review mentioned earlier, about 40% of patients reported better sleep after starting medical cannabis.⁶ In a large US survey of people with MS, sleep problems were the third most common reason people used cannabis, after spasticity and pain.¹⁰ Whether the sleep benefit comes directly from the cannabis or indirectly from less pain and spasticity at night is hard to untangle, and probably both are happening.

The Cognitive Price Tag

This is where the picture gets less comfortable. MS already damages cognition: processing speed, memory, and mental flexibility decline for many people over time. Cannabis appears to make that worse. A large cross-sectional study of people with MS found that cannabis use was associated with poorer processing speed and working memory, presenting a possible additional risk factor for cognitive impairment.¹¹

An MRI study comparing cannabis-using and non-using MS patients found that the cannabis group performed significantly worse on tests of spatial memory and information processing speed.¹² Another study using functional brain imaging found that cannabis users with MS had to recruit more widespread brain regions to accomplish the same cognitive tasks, and they still made more errors. On a demanding working memory task, cannabis users showed increased activation in brain areas associated with compensatory effort.¹³ In plain terms: their brains were working harder and doing worse.

These are cross-sectional studies, meaning they compare users to non-users at a single point in time rather than tracking what happens when someone starts or stops using. It’s possible that people whose cognition is already declining are more likely to try cannabis, which would make the association look worse than the actual causal effect. But the consistency across multiple studies and multiple cognitive measures is hard to dismiss. If you’re already noticing cognitive changes from MS, adding cannabis may accelerate the problem.

Depression and Psychiatric Risk

Many people with MS use cannabis hoping it will help their mood. Depression is extremely common in MS, much more so than in the general population, and the logic of using something that makes you feel better in the moment seems straightforward. The research suggests this logic may backfire. A study that tracked MS patients who either continued or withdrew from cannabis found that depression scores improved significantly in those who stopped using cannabis, while scores remained unchanged in those who continued. The researchers noted this as a “cautionary note,” since the people using cannabis to help their mood actually did better off it.¹⁴

Separately, a study comparing cannabis users and non-users with MS found that a higher proportion of cannabis users met criteria for a psychiatric diagnosis overall.¹⁵ Again, the direction of causation is debatable: people with more psychiatric burden might be more drawn to cannabis. But the depression finding, where stopping cannabis led to measurable improvement, is harder to explain away with that argument. At minimum, the idea that cannabis is a reliable mood booster for people with MS isn’t supported by the evidence available.

Smoking Versus Other Routes

The title question asks specifically about smoking, which is worth addressing head-on. Most of the clinical trial evidence for cannabis in MS does not come from smoking. The trials used pharmaceutical preparations: nabiximols (an oromucosal spray containing THC and CBD), oral cannabis extract capsules, or oral THC. Smoked cannabis has been studied directly in at least one rigorous trial and showed real benefit for spasticity, but it remains the less-studied delivery method in this population.

In practice, people with MS who use cannabis use a mix of methods. A cross-sectional survey of cannabis users with MS in Oregon and Southwest Washington found that smoking, vaping, topicals, tinctures and oils, and edibles were used at similar rates, roughly 35 to 46% each, and most users reported using more than one route. Across all methods, the majority of current and past users rated cannabis as very or somewhat beneficial for their MS.¹⁶

Smoking has distinct drawbacks that non-inhaled routes avoid. Inhaling combusted plant material exposes your lungs to tar, carbon monoxide, and irritants. For someone with MS who may already have reduced respiratory muscle strength or limited mobility for exercise, adding chronic lung irritation is a genuine concern. Vaping avoids combustion but carries its own uncertainties about long-term safety. Oral forms (capsules, edibles, tinctures) and oromucosal sprays eliminate respiratory risk entirely, though they take longer to kick in and are harder to dose precisely because absorption varies. For someone whose primary concern is spasticity or pain and who plans to use cannabis regularly, non-smoked routes are the safer bet for lung health.

What Neurologists Actually Recommend

The American Academy of Neurology produced two major evidence-based guidelines relevant here. Their recommendations are more specific than most patients realize, varying by symptom and by formulation:

• Spasticity symptoms: oral cannabis extract earned the strongest recommendation (Level A), meaning the evidence is strong enough to say it is effective. THC and nabiximols received “probably effective” ratings (Level B).
• Pain: oral cannabis extract earned Level A for pain excluding central neuropathic pain. THC and nabiximols were rated Level B.
• Bladder frequency: nabiximols was rated as probably effective for reducing daily bladder voids. THC and oral cannabis extract were rated as probably ineffective for broader bladder complaints.
• Tremor: all formulations were rated as probably or possibly ineffective. If tremor is your main problem, cannabis is unlikely to help.

These guidelines were based on the strongest recommendation system in neurology, but they were published in 2014 and the evidence base has grown since then.³⁹ Still, the basic takeaway hasn’t changed much: cannabis has its strongest evidence for subjective spasticity and pain relief, weaker evidence for bladder symptoms, and no evidence for tremor.

One thing the guidelines don’t tell you is what strain or dose to use, because the evidence simply doesn’t exist at that level of specificity. Most clinical trials used standardized pharmaceutical products, not the wildly variable products available at dispensaries. Your neurologist can tell you whether cannabis is reasonable for your symptoms but probably can’t tell you which product to buy.

Tolerance, Dependence, and Stopping

A common worry is whether long-term cannabis use for MS will lead to needing higher and higher doses, or to withdrawal symptoms if you stop. The evidence here is cautiously reassuring. A long-term open-label trial of nabiximols for MS spasticity found no evidence of tolerance developing over extended use, and patients who stayed in the study reported continued benefit. No psychoses or worrisome psychiatric trends emerged, and there were no withdrawal symptoms after abrupt cessation.¹⁷

A separate study that deliberately interrupted cannabis-based medicine for two weeks in MS patients found no consistent withdrawal syndrome, though about 46% of participants reported at least one mild symptom such as tiredness, interrupted sleep, mood changes, or vivid dreams.¹⁸ Those symptoms were mild and transient, not the kind of intense withdrawal you’d see with opioids or benzodiazepines. For the pharmaceutical preparations studied, the dependence risk appears to be low. Whether the same is true for high-THC dispensary products used daily is less certain, since those haven’t been studied as rigorously in this population.

Why the Endocannabinoid System Matters in MS

Cannabis doesn’t just happen to help some MS symptoms by accident. The body has its own endocannabinoid system, a network of signaling molecules and receptors that helps regulate inflammation, pain perception, muscle tone, and immune function, all of which go haywire in MS. Research has found that this system is genuinely disrupted in MS. In patients with relapsing MS, levels of the endocannabinoid anandamide were elevated in cerebrospinal fluid and in immune cells, with the increase driven by both higher production and slower breakdown of the molecule.¹⁹

This suggests the body is already trying to use its own cannabinoid signaling to fight back against the disease process, and that external cannabinoids from cannabis may be boosting a defense mechanism that’s already engaged. Preclinical research has shown that CBD in particular has anti-inflammatory and neuroprotective effects, raising interest in whether cannabinoids might do more than just manage symptoms and actually slow disease progression.²⁰ That’s still speculative and based mostly on lab and animal studies, not human trials. But it provides a biological rationale for why cannabis would interact with MS in the first place.

How Many People With MS Use Cannabis, and Why

Cannabis use among people with MS is substantially higher than in the general population. One study found that about 40% of MS patients reported having ever used marijuana, compared to about 33% of matched controls, and recent use was dramatically more common: roughly 9.4% of MS patients had used it in the past three months compared to just 0.4% of controls. Use was most common in younger patients and in men.²¹

A larger US survey found that 31% of respondents had ever used cannabis for MS symptoms, with 20% currently using it. The top three symptoms people were trying to treat were spasticity (80% of current users), pain (69%), and sleep problems (61%).¹⁰ Among those who had never tried it, the biggest barriers were lack of data about whether it works (40%), safety concerns (27%), legal worries (25%), and cost (18%). Those are reasonable barriers, and honestly, the first one is the most legitimate: for many specific MS symptoms beyond spasticity and pain, the data really is thin.

A survey asking MS patients who smoked cannabis to rate its effects on various symptoms found improvements reported for a wide range of issues, from spasticity and chronic pain (the most commonly improved) down through fatigue, sexual dysfunction, and bladder and bowel problems (reported by smaller percentages).²² Self-reported surveys like these tend to overestimate benefits because people who kept using cannabis are the ones who found it helpful, while those who tried it and got nothing likely stopped and didn’t report improvement. Still, the breadth of symptoms people report relief from hints that cannabis may be doing something more systemic than targeting any single symptom pathway.

Symptoms Cannabis Probably Won’t Help

For all the symptoms where cannabis shows promise, there are others where the evidence points toward “don’t bother.” Tremor is the clearest example. Both the AAN guideline and its systematic review concluded that THC, oral cannabis extract, and nabiximols are probably or possibly ineffective for tremor.⁹ If hand tremor or intention tremor is your most disabling symptom, cannabis is unlikely to be the answer.

Urinary incontinence (as opposed to urinary frequency) also didn’t respond in the AAN’s evidence review. And while patients often report improvements in fatigue, there’s little controlled trial data to back that up. The gap between what patients feel cannabis helps and what controlled studies confirm is widest for the less-studied symptoms. That doesn’t mean patients are wrong, it means we don’t have the data to know for sure. If you try cannabis for a symptom outside the evidence base, treat it as a personal experiment: give it a defined trial period, track whether the symptom actually changes, and be honest about the result.